ABVC BioPharma, Inc.

ABVC · NASDAQ

ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.

Follow Add to Watchlist Ask Question

NASDAQ ABVC Coverage Bootstrap Biotechnology Botanical Drugs Ophthalmology

Latest ReportMay 13, 2026ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balanceView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

OphthalmologyNasdaqBiotechnology

Clear tags

Match

Latest Thesis

ABVC BioPharma: zero revenue, $21M of assets, and a pipeline too wide for its cash balance

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

ABVC BioPharma, Inc.BioPharma: zero revenue, $21M of assets, and a pipeline too wideMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->